Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Mabwell (Shanghai) Bioscience Co., Ltd.
邁威(上海)生物科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2493)

ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Mabwell (Shanghai) Bioscience Co., Ltd. (the "**Company**") hereby announces that at the trade union committee held on June 18, 2026, Dr. Gui Xun ("**Dr. Gui**") was elected as the employee representative Director of the third session of the Board of the Company at the 7th meeting of the 1st session of the trade union committee of the Company cum employee representative meeting of the Company held on June 18, 2026. He will serve on the third session of the Board together with the Directors elected by the general meeting of the Company held on June 18, 2026, and his term of office shall commence on the date of election of Dr. Gui until the expiry of the term of the third session of the Board.

The biographical details of Dr. Gui are set out below:

Dr. GUI Xun (桂勛), aged 40, is an executive Director (employee representative Director) and a deputy general manager of our Company and is primarily responsible for overseeing early innovation research and molecular discovery. Dr. Gui was elected as an employee representative Director in December 2025. He has been our deputy general manager since June 2023. He also worked in our Company as the research assistant of the president from June 2019 to February 2023, a senior director and the head of the innovation and discovery department from September 2020 to February 2023 and a vice president since March 2023. He has been a director of the subsidiaries of the Company including Lianwei Chuanghe (Shanghai) Biotechnology Co., Ltd.(聯威創合(上海)生物技術有限公司)since March 2026 and Lianwei Chuangyuan (Shanghai) Biotechnology Co., Ltd. (聯威創源(上海)生物技術有限公司)since November 2025.

From January 2015 to May 2019, Dr. Gui worked at the University of Texas Health Science Center at Houston in the U.S. as a postdoctoral researcher. Dr. Gui received his bachelor's degree in biotechnology from Hunan University (湖南大學) in the PRC in June 2007. He obtained his master's degree in cell biology and doctorate degree in biochemistry and molecular biology from Xiamen University (廈門大學) in the PRC in September 2010 and June 2014, respectively. Dr. Gui completed his postdoctoral studies in tumor immunology and antibody drug development from the University of Texas Health Science Center at Houston in the U.S. in May 2019.

Dr. Gui indirectly holds 500,000 A shares of the Company through Ningbo Meishan Free Trade Port Zhenzhu Investment Management Partnership (Limited Partnership) (寧波梅山保税港區真珠投資管理合夥企業(有限合夥)).

As at the date of this announcement and to the best knowledge of the Board, save as disclosed herein:

(i) Dr. Gui has not held any other positions in the Company or any of its subsidiaries or directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years or have other major appointments and professional qualifications; (ii) Dr. Gui does not have any other relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company; and (iii) Dr. Gui does not hold any equity interest in the Company (within the meaning of Part XV of the Securities and Futures Ordinance).

The Company will enter into service contract with Dr. Gui for a term commencing from the date of the approval of his election at the employee representative meeting of the Company until the expiry of the term of the third session of the Board.

Under the terms of the service contract, Dr. Gui Xun as executive Director, he shall not be entitled to any additional Director's service fees or Director's allowances payable by the Company by virtue of his position as executive Director. If he holds other position(s) in the Company or the Group, he will receive salaries, bonuses, and other remuneration in accordance with his employment contracts.

Save as disclosed above, in respect of the appointment of Dr. Gui, there is no information required to be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to (v) of the Listing Rules nor are there any matters which need to be brought to the attention of the shareholders of the Company.

By Order of the Board
Mabwell (Shanghai) Bioscience Co., Ltd.
Dr. Liu Datao
Chairman of the Board and Executive Director

Shanghai, the PRC, June 18, 2026

As at the date of this announcement, the directors of the Company are: (i) Mr. Tang Chunshan, Dr. Liu Datao (Chairman of the Board), Dr. Wu Hai, Mr. Hua Jun and Dr. Gui Xun as executive directors; and (ii) Mr. Qin Zhengyu, Mr. Zhou Rui, Ms. Li Fan and Ms. Wang Fang as independent non-executive directors.